The scientific study of chemical processes, including metabolites, is known as metabolomics. Metabolomics is undoubtedly the careful study of the specific chemical traces that particular biological processes leave behind. The comprehensive measurement of all metabolites and low-molecular-weight compounds in biological material is the broad definition of the developing field of metabolomics. Metabolomics continues to show promise as a fundamental objective lens in the molecular microscope for precision medicine because it enables the profile of significantly more metabolites than are immediately covered by conventional clinical laboratory techniques.
According to this analysis, the Global Metabolomics Market was valued at ~US$ 1.5 billion in 2017. The availability of government and private funding for metabolomics research has driven the global metabolomics market's rapid expansion. A significant emphasis is being placed on cutting-edge methods that can effectively detect and treat life-threatening diseases, such as cancer and cardiovascular disease, owing to the prevalence and mortality rate of such diseases.
It is estimated to be ~US$ 2.5 billion in 2022 and is expected to reach a market size of ~US$ 5 billion by 2028 growing at a CAGR of ~12% during 2022-2028.
Metabolomics offers a rising focus on innovative approaches with significant potential due to the rise in life-threatening diseases like cancer neurological conditions, and coronary heart disease, which has resulted in a surge in both government and private investments in the industry.
Another factor promoting metabolomics market expansion is the combination of metabolomics and machine learning (ML). Nuclear Magnetic Resonance (NMR) and Multiple sclerosis (MS) data can be accurately interpreted with the use of machine learning (ML), which also automates employment, and complex processes.
A variety of heterogeneous data is generated by metabolomics techniques, and interpreting such data can be difficult and complex. Any analytical method cannot be used to analyze the data due to the chemical diversity of small molecule metabolites. The prosperity of the market as a whole is being impeded by all of such factors.
The metabolomics market has a potential impact from COVID-19. As a result of the utilization of metabolomics in research to understand COVID-19 diseases.
According to the Centers for Disease Control and Prevention (CDC), in January 2022, 6 out of 10 adults in the United States have a chronic disease, and 4 out of 10 persons have more than one or two. The high prevalence of chronic diseases necessitates the development of novel, cutting-edge therapies, increasing the use of metabolomics and fostering business expansion.
In June 2021, Bruker Corporation announced the launch of two new Tim stop instruments: Next-gen timsTOF Pro 2 with Unprecedented Proteomic Depth and tims TOF SCP for Unbiased Single Cell 4D-Proteomics.
Note:This is an On-Demand/Planned report, so the figures quoted here for a market size estimate, forecast, growth, segment share, and competitive landscape are based on initial findings and might vary slightly in the actual report. Also, any required customizations can be covered to the best feasible extent for Pre-booking clients, and the report delivered within a maximum of two working weeks.
According to this analysis, the Global Metabolomics Market was valued at ~US$ 1.5 billion in 2017. The availability of government and private funding for metabolomics research has driven the global metabolomics market's rapid expansion. A significant emphasis is being placed on cutting-edge methods that can effectively detect and treat life-threatening diseases, such as cancer and cardiovascular disease, owing to the prevalence and mortality rate of such diseases.
It is estimated to be ~US$ 2.5 billion in 2022 and is expected to reach a market size of ~US$ 5 billion by 2028 growing at a CAGR of ~12% during 2022-2028.
Metabolomics offers a rising focus on innovative approaches with significant potential due to the rise in life-threatening diseases like cancer neurological conditions, and coronary heart disease, which has resulted in a surge in both government and private investments in the industry.
Another factor promoting metabolomics market expansion is the combination of metabolomics and machine learning (ML). Nuclear Magnetic Resonance (NMR) and Multiple sclerosis (MS) data can be accurately interpreted with the use of machine learning (ML), which also automates employment, and complex processes.
A variety of heterogeneous data is generated by metabolomics techniques, and interpreting such data can be difficult and complex. Any analytical method cannot be used to analyze the data due to the chemical diversity of small molecule metabolites. The prosperity of the market as a whole is being impeded by all of such factors.
The metabolomics market has a potential impact from COVID-19. As a result of the utilization of metabolomics in research to understand COVID-19 diseases.
Scope of the Report
The Global Metabolomics Market is segmented into By Products and Services, Indications, and Applications. In addition, the report also covers market size and forecasts for the four regions. The revenue used to size and forecast the market for each segment is US$ BillionBy Product and Services
- Metabolomics Instrument
- Metabolomics bioinformatics tools and services
By Indication
- Cancer
- Cardiovascular Disorders
- Neurological Disorders
- Inborn Errors of Metabolism
- Metabolic Disorders
- Others
By Application
- Biomarker Discovery
- Toxicology
- Nutrigenomics
- Personalized Medicine
- Drug Discovery
- Functional Genomics
- Other
By Geography
- North America (USA, Canada, and Mexico)
- Europe (France, Italy, Germany, Spain, UK, and Rest of Europe)
- Asia Pacific (China, India, Japan, South Korea, Australia, and Rest of Asia Pacific)
- LAMEA (Latin America, Middle East, and Africa)
Key Players
- Agilent Technologies, Inc
- Danaher
- Shimadzu Corporation
- Waters Corporation
- Bruker
- Human Metabolome Technologies Inc
- Thermo Fisher Scientific
- LECO Corporation
- Metabolon INC
- PerkinElmer Inc
Key Trends by Market Segment
By Product and Services - TheMetabolomics Instrument by Product and Services dominated the market in 2021, due to the extensive utilization of market products in research activities around the world in the disciplines of medicine, nutraceuticals, and metabolomics.- The growth is attributed to the rapid acceptance of metabolomics and smooth technological operations, which leads to increased workflow efficiency, precision, dependability, and data processing
- During the forecast period, factors such as the technical improvements in analytical instruments in terms of miniaturization, automation, and computerization, and the improvement of healthcare infrastructure in developing countries for effective illness detection and treatment are anticipated to drive the growth of the segment
- By Indication - The Cancer segment accounted for the highest market share in 2021, owing to the rise in cancer incidence around the globe and the expansion of oncological research projects
- According to World Health Organization (WHO), in February 2022 stated that Cancer is the leading cause of death throughout the world, accounting for nearly 10 million deaths in 2020, or nearly one in each six
- According to the American Cancer Society, in 2021, there will be an estimated 19 million new cancer cases diagnosed and 608,570 cancer deaths in the United States
- By Application - Biomarker Discovery accounted for the highest market share in 2021 owing to the worldwide increase in the prevalence of chronic diseases such as Cancer, Chronic Obstructive Pulmonary Disease (COPD), and Arthritis
- The market's bigger contribution to the discovery of new biomarkers is also driven by extensive oncological research with a preference for the study of such markers and their application in the treatment of cancer
- Metabolic biomarkers are rapidly being utilized to assess patients' pathophysiological health conditions Metabolomics has evolved in recent years into a crucial tool for identifying biomarkers as a result of major technological advancements
- By Geography: North Americaa ccounted for the largest market share among all regions in 2021, owing to the presence of major Metabolomics studies and testing organizations like Agilent Technologies, Inc., Danaher, Waters Corporation, Bruker, and many more
According to the Centers for Disease Control and Prevention (CDC), in January 2022, 6 out of 10 adults in the United States have a chronic disease, and 4 out of 10 persons have more than one or two. The high prevalence of chronic diseases necessitates the development of novel, cutting-edge therapies, increasing the use of metabolomics and fostering business expansion.
Competitive Landscape
The Global Metabolomics Market is highly competitive with ~200 players which include globally diversified players, regional players as well as a large number of country-niche players each with their niche in Metabolomics research and testing. Large global players constitute ~20% of competitors, while country niche players represent the largest number of competitors. New drug discoveries are increasingly in demand. The demand for metabolomics is rising since it is used to test prospective biomarkers (certain cells, chemicals, genes, gene products, enzymes, or hormones) to assess the responsiveness of cancer therapy and enable early detection. The market is expanding as a result of strategic actions such as partnerships, collaborations, mergers, acquisitions, new product launches, and the rising demand for cutting-edge technologies. Some of the major players in the market include Agilent Technologies, Inc., Danaher, Shimadzu Corporation, Waters Corporation, Bruker, Human Metabolome Technologies Inc., Thermo Fisher Scientific, LECO Corporation, Metabolon INC, PerkinElmer Inc., and others.Recent Developments Related to Major Players
In March 2020, Danaher Corporation announced that it had successfully acquired the Life Sciences section of General Electric Company's Biopharma business. The company will be a stand-alone operating company within Danaher's Life Sciences division and will be a part of Danaher under the name Cytiva.In June 2021, Bruker Corporation announced the launch of two new Tim stop instruments: Next-gen timsTOF Pro 2 with Unprecedented Proteomic Depth and tims TOF SCP for Unbiased Single Cell 4D-Proteomics.
Conclusion
The Global Metabolomics Market is anticipated to grow significantly during the projected period (2022-2028) owing to the growing availability of government and corporate funding for metabolomics research, increasing R&D expenditure in the pharmaceutical and biopharmaceutical industry, and ongoing improvements in metabolomics technologies driving the expansion of the global metabolomics market during the anticipated period. Though the market is competitive with ~200 participants, country-niche players control the dominant share and regional players also hold a significant share.Note:This is an On-Demand/Planned report, so the figures quoted here for a market size estimate, forecast, growth, segment share, and competitive landscape are based on initial findings and might vary slightly in the actual report. Also, any required customizations can be covered to the best feasible extent for Pre-booking clients, and the report delivered within a maximum of two working weeks.
Key Topics Covered in the Report
- Snapshot of Metabolomics Market
- Industry Value Chain and Ecosystem Analysis
- Market size and Segmentation of the Metabolomics Market
- Historic Growth of the Overall Metabolomics Market and Segments
- Competition Scenario of the Market and Key Developments of Competitors
- Porter’s 5 Forces Analysis of the Metabolomics Market Industry
- Overview, Product and Services Offerings, and Strengths & Weaknesses of Key Competitors
- COVID-19 Impact on the Overall Metabolomics Market
- Future Market Forecast and Growth Rates of the Total Metabolomics Market and by Segments
- Market Size of Segments with Historical CAGR and Future Forecasts
- Analysis of the Metabolomics Market in Global Regions
- Major Metabolomics Type/Supply and Consumption/Demand Hubs in the Region
- Region-wise Historic and Future Market Growth Rates of the Total Market and Segments
- Overview of Notable Emerging Competitor Companies within the Region
Notable Key Players Mentioned in the Report
- Agilent Technologies, Inc
- Danaher
- Shimadzu Corporation
- Waters Corporation
- Bruker
- Human Metabolome Technologies Inc
- Thermo Fisher Scientific
- LECO Corporation
- Metabolon INC
- PerkinElmer Inc
- Million Marker
- Prometheus Metabolomics
- Afekta Technologies Ltd
- Adapsyn Bioscience Inc
- QuLab Medical Ltd
Key Target Audience - Organizations and Entities Who Can be benefited by Subscribing This Report
- Manufacturers of Metabolomics
- Distributors, Suppliers, and Sales Channels
- Emerging and Startup Companies in Metabolomics
- Metabolomics Manufacturers
- Market research and consulting firms
- Organizations, forums, and alliances related to Metabolomics
- Metabolomics Testers
- Global Metabolomics manufacturers, suppliers, distributors, and other stakeholders
- Associations, organizations, forums, and alliances related to Metabolomics
- Government bodies such as regulating authorities and policymakers
Time Period Captured in the Report
- Historical Period: 2017-2021
- Forecast Period: 2022E-2028F
Frequently Asked Questions
What is the Study Period of this Market Report?- The Global Metabolomics Market is covered from 2017-2028 in this report, which includes a forecast for the period 2022-2028
- The Global Metabolomics Market is expected to witness a CAGR of ~12% over the next six years
- The rise in government and private organization financing for technical research, as well as the expansion of key players' partnerships and collaborations for the improvement of its product portfolio, are expected to be the primary driver of this market
- The metabolomics instrument segment held the largest share of the global metabolomics market in 2021
- Agilent Technologies, Inc., Danaher, Shimadzu Corporation, Waters Corporation, Bruker, Human Metabolome Technologies Inc, Thermo Fisher Scientific, LECO Corporation, Metabolon INC, PerkinElmer Inc., and others are the major companies operating in the Global Metabolomics Market
Additional benefits of purchasing an enterprise license:
- TAM/SAM/SOM Analysis
- Customer Cohort Analysis
- Marketing Initiatives
- White Space Opportunity Analysis
- Interactive Data Visualizations
- Customization: 20 Analyst Hours
- 3 Months Post Sales Analyst Support
- Complimentary Update Next Year
- Custom Webinars
Table of Contents
1. Executive Summary
2. Market Overview and Key Trends Impacting Growth
3. Total Global - Market Segmentation By Product and Services, Historic Growth, Outlook & Forecasts
4. Total Global - Market Segmentation by Indication Type, Historic Growth, Outlook & Forecasts
5. Total Global - Market Segmentation by Application, Historic Growth, Outlook & Forecasts
6. Application/Competition Analysis - Competitive Landscape
7. Key Competitor Profiles (Company Overview, Strengths & Weakness of Key Competitors)
8. Geographic Analysis & Major Region Market Historic Growth, Outlook, and Forecasts
9. Application Expert’s Opinions/Perspectives
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Agilent Technologies, Inc.
- Danaher
- Shimadzu Corporation
- Waters Corporation
- Bruker
- Human Metabolome Technologies Inc
- Thermo Fisher Scientific
- LECO Corporation
- Metabolon INC
- PerkinElmer Inc.
- Million Marker
- Prometheus Metabolomics
- Afekta Technologies Ltd.
- Adapsyn Bioscience Inc.
- QuLab Medical Ltd
